Maze Therapeutics, Inc.
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.25 USD
18.38 M USD
167.50 M USD
26.11 M
About Maze Therapeutics, Inc.
Sector
Industry
CEO
Jason V. Coloma
Website
Headquarters
San Francisco
Founded
2017
IPO date
Jan 31, 2025
Identifiers
3
ISIN US5787841007
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MAZE is 48.12 USD — it has decreased by −1.91% in the past 24 hours. Watch Maze Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Maze Therapeutics, Inc. stocks are traded under the ticker MAZE.
MAZE stock has fallen by −0.04% compared to the previous week, the month change is a 20.15% rise, over the last year Maze Therapeutics, Inc. has showed a 266.77% increase.
We've gathered analysts' opinions on Maze Therapeutics, Inc. future price: according to them, MAZE price has a max estimate of 60.00 USD and a min estimate of 43.00 USD. Watch MAZE chart and read a more detailed Maze Therapeutics, Inc. stock forecast: see what analysts think of Maze Therapeutics, Inc. and suggest that you do with its stocks.
MAZE reached its all-time high on Jan 23, 2026 with the price of 47.36 USD, and its all-time low was 6.71 USD and was reached on Apr 9, 2025. View more price dynamics on MAZE chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MAZE stock is 6.92% volatile and has beta coefficient of 0.96. Track Maze Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Maze Therapeutics, Inc. there?
Today Maze Therapeutics, Inc. has the market capitalization of 2.30 B, it has increased by 1.65% over the last week.
Yes, you can track Maze Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Maze Therapeutics, Inc. is going to release the next earnings report on Apr 6, 2026. Keep track of upcoming events with our Earnings Calendar.
MAZE earnings for the last quarter are −0.66 USD per share, whereas the estimation was −0.71 USD resulting in a 6.80% surprise. The estimated earnings for the next quarter are −0.71 USD per share. See more details about Maze Therapeutics, Inc. earnings.
Maze Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
MAZE net income for the last quarter is −30.09 M USD, while the quarter before that showed −33.68 M USD of net income which accounts for 10.67% change. Track more Maze Therapeutics, Inc. financial stats to get the full picture.
No, MAZE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 10, 2026, the company has 125 employees. See our rating of the largest employees — is Maze Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Maze Therapeutics, Inc. EBITDA is −131.96 M USD, and current EBITDA margin is 36.35%. See more stats in Maze Therapeutics, Inc. financial statements.
Like other stocks, MAZE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Maze Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Maze Therapeutics, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Maze Therapeutics, Inc. stock shows the buy signal. See more of Maze Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.